Knight Therapeutics Inc. announced that it has entered into an exclusive License Agreement with Puma Biotechnology, Inc. granting Knight the exclusive right to commercialize NERLYNX® (neratinib) in Canada. Puma filed a New Drug Submission for NERLYNX® with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Under the terms of the License Agreement, Knight will be responsible for all commercial activities and future regulatory submissions for NERLYNX® in Canada. Puma will receive upfront and milestone payments up to $7.2 million throughout the term of this agreement, as well as double digit royalties on net sales of NERLYNX® in Canada.